Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, and Pharmacokinetics of Single and Multiple Ascending Dose of RP3128 in HV and Effect on LAR to Allergen Challenge in Mild Asthmatics

Next Previous
Trial Profile

A Phase I/IIa, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, and Pharmacokinetics of Single and Multiple Ascending Dose of RP3128 in HV and Effect on LAR to Allergen Challenge in Mild Asthmatics

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RP 3128 (Primary)
  • Indications Asthma
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Rhizen Pharmaceuticals

Most Recent Events

  • 21 Mar 2018 Status changed from recruiting to discontinued.
  • 01 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
  • 01 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top